This paper is only available as a PDF. To read, Please Download here.
Abstract
ChromosorbR column chromatography was used for separation of RU 486 from its immunologically
cross-reacting metabolites prior to quantitative analysis by radioimmunoassay (RIA)
or high-performanceliquid chromatography (HPLC). The results of the two assay methods
were in good agreement with each other (r=0.99, n=29). The retention time of RU 486
in our HPLC system was 2.5 min.
Plasma concentrations of RU 486 were measured by HPLC up to 48 h following single
oral administration of 100, 400, 600 and 800 mg of RU 486 to female volunteers. The
plasma peak concentrations (2.0 – 2.5 μg/ml) were reached within the first hour. After
redistribution, the plasma concentrations of RU 486 were not significantly affected
by the doses studied but remained in the same range throughout the 48 hours. The plasma
half-life between 24 and 48 hours was 27 hours or more.
We conclude that HPLC is valuable in studies on the metabolism and pharmacokinetics
of RU 486, but a less laborious RIA method after ChromosorbR column chromatography is suitable and gives reliable results in large-scale clinical
studies.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to ContraceptionAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- (Abstract No. 668.)RU 486: a new lead for steroidal anti-hormones.in: Sixty-Fourth Annual Meeting of the Endocrine Society, San Francisco, June 16 to 181982
- (Abstract No. 1463.)RU 38486 — A potent antiglucocorticoid in vivo.in: VIII International Congress of Pharmacology, Tokyo, July 19 to 241981
- RU 38486: Potent antiglucocorticoid activity correlated with strong binding to the cytosolic glucocorticoid receptor followed by an impaired activation.J. Steroid Biochem. 1984; 20: 271-276
- The effects of an antiprogesterone steroid on women: interruption of the menstrual cycle and of early pregnancy.C. R. Acad. Sc. Paris. 1982; 294: 933-938
- Endometrial and pituitary reponses to the steroidal antiprogestin RU 486 in postmenopausal women.J. Clin. Endocrinol. Metab. 1985; 60: 156-163
- Radioimmunoassay of RU 486.in: Segal S.J. Baulieu E.E. The Antiprogesterone Steroid RU 486 and Human Fertility Control. Plenum Press, Heidelberg1985: 99-101
- Segal S.J. Baulieu E.E. Proceedings on RU 486. Bellagio, New York1984
- Endocrinologic effects of the antiprogesterone RU 486 in the luteal phase of normal women.in: Segal S.J. Baulieu E.E. The Antiprogesterone Steroid RU 486 and Human Fertility Control. Plenum Press, Italy1985: 285-293
- Binding of the antiprogestin RU-486 to rat ovary steroid receptors.Contraception. 1983; 28: 77-85
- Development of antiglucocorticoids with potential clinical usefulness.in: Progress in Research and Clinical Applications of Corticosteroids. Heyden and Son Inc., New York1982: 152-176
- Pharmacokinetics of RU 486.in: Segal S.J. Baulieu E.E. The Antiprogesterone Steroid RU 486 and Human Fertility Control. Plenum Press, Philadelphia1985: 103-122
- The new steroid analog RU 486 inhibits glucocorticoid action in man.J. Clin. Endocrinol. Metab. 1984; 59: 25-28
- RU 486 inhibits peripheral effects of glucocorticoids in humans.J. Clin. Endocrinol. Metab. 1985; 61: 1009-1011
Article info
Publication history
Accepted:
December 4,
1986
Received:
January 14,
1986
Footnotes
*This work was undertaken as part of the contraceptive development program sponsored and coordinated by the International Committee for Contraception Research of the Population Council, Inc., New York, New York.
Identification
Copyright
© 1987 Geron-X, Inc. Published by Elsevier Inc. All rights reserved.
